Home & ambulatory infusion
A denied infusion claim is a five-figure loss. Clear it before the chair is booked.
Infusion is the only outpatient setting where a denial means you already bought the inventory. The drug is dispensed, the nurse is paid, and the claim is a coin flip on coverage and auth. Undersign clears the encounter — drug, dose, site of care — before you commit the vial. If a cleared claim is denied anyway, we pay contracted value within 30 days.
In every other specialty a denial costs margin. In infusion it costs inventory.
home-infusion market growth — every new referral is working capital at risk
working capital at risk on a single denied claim
days to guaranteed payment on cleared-then-denied encounters
In your workflow
Where the guarantee plugs in.
Clear the regimen
Payer, member, J-code + admin CPTs, site of care, planned schedule. The engine underwrites the whole course, not one date of service.
Buy on cleared
cleared means buy the drug. step_up means the auth or benefit needs one more document — flagged in intake, not after the vial is compounded.
A bad week, not a bad quarter
Eligibility, coverage, or auth denial on a cleared encounter: contracted value paid within 30 days. On claims this size, that's the whole point.
Infusion, visualized
The drip line.
grt_01J9ZKQ4T7Referral to guaranteed claim, in the order that protects the inventory.
What changes
Three lines on your P&L, rewritten.
Protect working capital
Never commit five figures of drug spend against an unpriced coverage risk again.
Underwriting that matches claim size
Basis-points pricing means high-value claims carry proportional protection — the economics were designed for exactly this asymmetry.
Pharmacy and billing stop arbitrating
Pharmacy dispenses on cleared; billing stops litigating whether intake “really” verified the benefit. The API is the referee.
Fair questions
Asked by every infusion operator we talk to.
“Our specialty pharmacy partner verifies benefits.”
Benefit verification is a snapshot of a moving target. The question infusion CFOs actually have is: who owns the claim if the snapshot ages badly? Today, you. Under a guarantee, us.
“Payers fight big claims harder.”
Correct — which is why more than half of appealed denials eventually pay. Payers are pricing your willingness to fight. A counterparty whose business model is the appeal changes that game.
“Can you really price this?”
Only with data — which is why we're running shadow-mode measurement per payer, per J-code, per region before any guarantee is sold. When we can't price a regimen, we say so. That honesty is the product.
The API is in development
Be first on the ledger.
Infusion is the highest-stakes market we'll serve — pilots open after our loss data seasons. Reserve your place.